Because its glucose-lowering effect is not operated by either insulin secretion or insulin sensitivity, the concern for hypoglycemia is scarce by a sole administration of this agent for the treatment of type 2 diabetes (T2DM). The gene discussed is INS; the disease is type 2 diabetes mellitus.